CN1593636A - 一种柴胡口腔崩解片及其制备方法 - Google Patents
一种柴胡口腔崩解片及其制备方法 Download PDFInfo
- Publication number
- CN1593636A CN1593636A CN 200410049853 CN200410049853A CN1593636A CN 1593636 A CN1593636 A CN 1593636A CN 200410049853 CN200410049853 CN 200410049853 CN 200410049853 A CN200410049853 A CN 200410049853A CN 1593636 A CN1593636 A CN 1593636A
- Authority
- CN
- China
- Prior art keywords
- oral cavity
- cavity disintegration
- radix bupleuri
- disintegration tablet
- disintegrating agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 43
- 241000202726 Bupleurum Species 0.000 title abstract description 7
- 239000006191 orally-disintegrating tablet Substances 0.000 title abstract description 4
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 52
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims abstract description 29
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims abstract description 29
- 239000000463 material Substances 0.000 claims abstract description 15
- 150000001875 compounds Chemical class 0.000 claims abstract description 14
- 239000000469 ethanolic extract Substances 0.000 claims abstract description 7
- 229920000858 Cyclodextrin Polymers 0.000 claims abstract description 4
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims abstract description 4
- 210000000214 mouth Anatomy 0.000 claims description 80
- 235000019414 erythritol Nutrition 0.000 claims description 33
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 30
- 239000004386 Erythritol Substances 0.000 claims description 28
- 229940009714 erythritol Drugs 0.000 claims description 28
- 238000000605 extraction Methods 0.000 claims description 25
- 239000000284 extract Substances 0.000 claims description 21
- 238000002481 ethanol extraction Methods 0.000 claims description 20
- 125000002057 carboxymethyl group Chemical class [H]OC(=O)C([H])([H])[*] 0.000 claims description 17
- 239000011734 sodium Substances 0.000 claims description 15
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 14
- 229910052708 sodium Inorganic materials 0.000 claims description 14
- 238000001035 drying Methods 0.000 claims description 13
- 238000010828 elution Methods 0.000 claims description 12
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 12
- 239000000706 filtrate Substances 0.000 claims description 11
- 229920002101 Chitin Polymers 0.000 claims description 10
- 239000011347 resin Substances 0.000 claims description 10
- 229920005989 resin Polymers 0.000 claims description 10
- 239000003463 adsorbent Substances 0.000 claims description 9
- 239000007864 aqueous solution Substances 0.000 claims description 9
- 239000012567 medical material Substances 0.000 claims description 9
- -1 filter Substances 0.000 claims description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 8
- 238000012856 packing Methods 0.000 claims description 7
- 239000002904 solvent Substances 0.000 claims description 7
- 238000003756 stirring Methods 0.000 claims description 7
- 238000000194 supercritical-fluid extraction Methods 0.000 claims description 7
- 238000005406 washing Methods 0.000 claims description 7
- 229920002472 Starch Polymers 0.000 claims description 6
- 230000001351 cycling effect Effects 0.000 claims description 6
- 239000000945 filler Substances 0.000 claims description 6
- 239000000796 flavoring agent Substances 0.000 claims description 6
- 235000019634 flavors Nutrition 0.000 claims description 6
- 239000008187 granular material Substances 0.000 claims description 6
- 238000005469 granulation Methods 0.000 claims description 6
- 230000003179 granulation Effects 0.000 claims description 6
- 239000000314 lubricant Substances 0.000 claims description 6
- 238000010298 pulverizing process Methods 0.000 claims description 6
- 239000008107 starch Substances 0.000 claims description 6
- 235000019698 starch Nutrition 0.000 claims description 6
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 5
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 5
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 5
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical class OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 5
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 4
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 4
- 229920002678 cellulose Polymers 0.000 claims description 4
- 239000001913 cellulose Substances 0.000 claims description 4
- 235000010980 cellulose Nutrition 0.000 claims description 4
- 235000019359 magnesium stearate Nutrition 0.000 claims description 4
- 239000013081 microcrystal Substances 0.000 claims description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 4
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 4
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 claims description 4
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims description 3
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 3
- 229940013618 stevioside Drugs 0.000 claims description 3
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 claims description 3
- 235000019202 steviosides Nutrition 0.000 claims description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- 229930195725 Mannitol Natural products 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 238000001179 sorption measurement Methods 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 18
- 230000000144 pharmacologic effect Effects 0.000 abstract description 4
- 230000009471 action Effects 0.000 abstract description 3
- 239000004480 active ingredient Substances 0.000 abstract description 2
- 239000002552 dosage form Substances 0.000 abstract description 2
- 229920001661 Chitosan Polymers 0.000 abstract 1
- 239000002131 composite material Substances 0.000 abstract 1
- 238000011835 investigation Methods 0.000 abstract 1
- 239000003826 tablet Substances 0.000 description 76
- 239000007788 liquid Substances 0.000 description 19
- 238000002474 experimental method Methods 0.000 description 13
- 239000007924 injection Substances 0.000 description 13
- 238000002347 injection Methods 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 239000004615 ingredient Substances 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 10
- 230000000694 effects Effects 0.000 description 8
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 230000008961 swelling Effects 0.000 description 7
- 239000000341 volatile oil Substances 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 6
- 239000013558 reference substance Substances 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 208000000114 Pain Threshold Diseases 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 4
- 230000037040 pain threshold Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 4
- 229930182490 saponin Natural products 0.000 description 4
- 150000007949 saponins Chemical class 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- 230000009102 absorption Effects 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000000202 analgesic effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000001256 steam distillation Methods 0.000 description 3
- 235000019605 sweet taste sensations Nutrition 0.000 description 3
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 210000005069 ears Anatomy 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 240000006409 Acacia auriculiformis Species 0.000 description 1
- 206010008531 Chills Diseases 0.000 description 1
- 206010013183 Dislocation of vertebra Diseases 0.000 description 1
- 206010014025 Ear swelling Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 102000004317 Lyases Human genes 0.000 description 1
- 108090000856 Lyases Proteins 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000000680 avirulence Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000009748 deglutition Effects 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
Description
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100498530A CN1313103C (zh) | 2004-06-25 | 2004-06-25 | 一种柴胡口腔崩解片及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100498530A CN1313103C (zh) | 2004-06-25 | 2004-06-25 | 一种柴胡口腔崩解片及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1593636A true CN1593636A (zh) | 2005-03-16 |
CN1313103C CN1313103C (zh) | 2007-05-02 |
Family
ID=34665845
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2004100498530A Expired - Lifetime CN1313103C (zh) | 2004-06-25 | 2004-06-25 | 一种柴胡口腔崩解片及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1313103C (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101428049B (zh) * | 2008-12-11 | 2011-08-31 | 江苏省中国科学院植物研究所 | 抗上呼吸道感染的药物组合物及其制备方法和应用 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1148977A (zh) * | 1996-08-25 | 1997-05-07 | 重庆祥慧医药高新技术研究所 | 乙肝宁胶囊的配方及其生产工艺 |
-
2004
- 2004-06-25 CN CNB2004100498530A patent/CN1313103C/zh not_active Expired - Lifetime
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101428049B (zh) * | 2008-12-11 | 2011-08-31 | 江苏省中国科学院植物研究所 | 抗上呼吸道感染的药物组合物及其制备方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
CN1313103C (zh) | 2007-05-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101040915A (zh) | 一种双黄连注射液的制备方法及其成分检测方法 | |
CN1557842A (zh) | 玉竹多糖的提取方法、药物制剂制备方法及其用途 | |
CN1593634A (zh) | 一种养血清脑口腔崩解片及其制备方法 | |
CN1186051C (zh) | 一种化痰止咳的药物及其生产方法 | |
CN1593636A (zh) | 一种柴胡口腔崩解片及其制备方法 | |
CN1857385A (zh) | 一种治疗颈椎病的药物组合物及其制备方法 | |
CN1872326A (zh) | 一种治疗痔疮的外用药物组合物及其制备方法 | |
CN1278674C (zh) | 一种清咽口腔崩解片及其制备方法 | |
CN1301108C (zh) | 美他多辛分散片及其制备方法 | |
CN1259037C (zh) | 一种抗病毒口腔崩解片及其制备方法 | |
CN1271995C (zh) | 一种心痛宁口腔崩解片及其制备方法 | |
CN1415318A (zh) | 一种用于治疗糖尿病的中药制剂及制备方法 | |
CN1293895C (zh) | 一种喉症口腔崩解片及其制备方法 | |
CN1586593A (zh) | 一种野菊花口腔崩解片及其制备方法 | |
CN1277569C (zh) | 一种生脉口腔崩解片及其制备方法 | |
CN1586555A (zh) | 一种桂枝茯苓口腔崩解片及其制备方法 | |
CN1593635A (zh) | 一种藿香正气口腔崩解片及其制备方法 | |
CN1593627A (zh) | 一种百宝丹口腔崩解片及其制备方法 | |
CN1586594A (zh) | 一种金莲花口腔崩解片及其制备方法 | |
CN1593615A (zh) | 一种脉络宁口腔崩解片及其制备方法 | |
CN1278705C (zh) | 一种通心络口腔崩解片及其制备方法 | |
CN1586534A (zh) | 一种脑安口腔崩解片及其制备方法 | |
CN1565611A (zh) | 一种治疗肩周炎的中药组合物及其制备方法 | |
CN1593633A (zh) | 一种血栓通口腔崩解片及其制备方法 | |
CN1891265A (zh) | 一种参附口腔崩解片及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: GUANGDONG TIANZHIJIAO LIFE SCIENCE CO., LTD. Free format text: FORMER OWNER: ZHANG QINGLONG Owner name: TIANJIN TASLY PHARMACEUTICAL CO., LTD. Effective date: 20050422 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20050422 Address after: 510610 Guangzhou Tianhe District City Lin Road No. 150, Tianyu Garden Plaza Accord Room 802 Applicant after: GUANGDONG TIANZHIJIAO LIFE SCI Co-applicant after: TIANJIN TASLY PHARMACEUTICAL Co.,Ltd. Address before: 100036, 1, building 1, 1801, Lianhua District, Beijing, Haidian District Applicant before: Zhang Qinglong |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee | ||
CP01 | Change in the name or title of a patent holder |
Address after: 510610 Guangzhou Tianhe District City Lin Road No. 150, Tianyu Garden Plaza Accord Room 802 Co-patentee after: TASLY PHARMACEUTICAL GROUP Co.,Ltd. Patentee after: GUANGDONG TIANZHIJIAO LIFE SCI Address before: 510610 Guangzhou Tianhe District City Lin Road No. 150, Tianyu Garden Plaza Accord Room 802 Co-patentee before: TIANJIN TASLY PHARMACEUTICAL Co.,Ltd. Patentee before: GUANGDONG TIANZHIJIAO LIFE SCI |
|
CX01 | Expiry of patent term |
Granted publication date: 20070502 |